If you see patients asking about high-dose vitamin C (ascorbate) with chemotherapy, here’s the quick read. Early human studies suggest potential benefit in select cancers, but this remains investigational and dose dependent. Safety looks manageable with screening, and larger randomized trials are still needed.

1. From Bench to Bedside

A biochemist with myelodysplastic syndromes (MDS) applied his own vitamin C science to care. He receives azacitidine on a 28-day cycle with 75 g ascorbate on select days, given back to back. He reports feeling well with near-normal counts, and his oncologist is now recruiting for an MDS trial.

2. How We Got Here

Earlier oral vitamin C trials were negative, which fueled skepticism. The key miss was route and achievable levels, since oral dosing can’t reach pharmacologic concentrations. Interest returned with IV ascorbate work, and the doses studied are far beyond store-bought tablets.

3. What Really Drives It

This isn’t an antioxidant story at treatment doses. IV ascorbate can reach near 20 mM and behaves as a prooxidant that is thought to generate hydrogen peroxide around tumors. Preclinical data show selective damage in tumor cells, and human studies confirm achievable millimolar blood levels.

4. Signals in Humans

Early studies hint at benefit across several cancers. In metastatic pancreatic cancer, 75 g three times weekly was associated with improved survival. Glioblastoma and bladder signals emerged, while a colorectal trial was negative overall.

5. Safety and Next Steps

If you consider this treatment, dose matters and blood levels should reach 15 to 20 mM. Adverse events are usually mild; screen for G6PD, renal disease, and kidney stones. Effectiveness needs phase 3 confirmation, and funding remains a barrier despite low per-dose cost.

Bottom Line

High-dose IV ascorbate remains investigational but shows signals worth watching. If you discuss it with patients, emphasize dosing to reach pharmacologic levels and screen carefully for safety. Consider referral to trials while we wait for phase 3 confirmation and funding solutions.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.